Abstract
The only pharmacological treatment for acute ischaemic stroke used at present is tissue plasminogen activator. The nitrone NXY-049 has been shown to be neuroprotective in a variety of animal models. The SAINT (Stoke Acute Ischemic NXY-059 Treatment) 1 trial has shown that, on the modified Rankin scale at 90 days, there were slightly more patients with no symptoms in the NXY-059 group than the placebo group. Conversely, there were slightly fewer patients with a score of 4 (moderately-severe disability) in the NXY-059 group than placebo group. NXY-059 was well tolerated. These data suggest that NXY-059 may be a modest advancement for the treatment of acute ischaemic stroke.
Original language | English |
---|---|
Pages (from-to) | 965-968 |
Number of pages | 4 |
Journal | Expert Opinion on Pharmacotherapy |
Volume | 7 |
Issue number | 7 |
DOIs |
|
Publication status | Published - 2006 |